KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Accounts Payables: 2009-2024

Historic Accounts Payables for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $789.5 million.

  • Regeneron Pharmaceuticals' Accounts Payables rose 81.74% to $903.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $903.8 million, marking a year-over-year increase of 81.74%. This contributed to the annual value of $789.5 million for FY2024, which is 30.15% up from last year.
  • Regeneron Pharmaceuticals' Accounts Payables amounted to $789.5 million in FY2024, which was up 30.15% from $606.6 million recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' Accounts Payables ranged from a high of $789.5 million in FY2024 and a low of $475.5 million during FY2020.
  • Its 3-year average for Accounts Payables is $661.8 million, with a median of $606.6 million in 2023.
  • Data for Regeneron Pharmaceuticals' Accounts Payables shows a peak YoY surged of 30.15% (in 2024) over the last 5 years.
  • Regeneron Pharmaceuticals' Accounts Payables (Yearly) stood at $475.5 million in 2020, then rose by 18.61% to $564.0 million in 2021, then grew by 4.47% to $589.2 million in 2022, then grew by 2.95% to $606.6 million in 2023, then surged by 30.15% to $789.5 million in 2024.